In this issue:
The cost of teriflunomide treatment for RRMS
Risk tolerance to MS therapies
Safety and efficacy of AHSCT after natalizumab discontinuation
Disability progression in SPMS patients treated with rituximab
Ocrelizumab is effective across all subgroups of patients with RRMS
Early diagnosis of PML
AHSCT for treatmentrefractory MS
Natalizumab anti-drug antibodies persistency
Safety of cladribine tablets in patients with MS
Ocrelizumab infusion-related reactions
Please login below to download this issue (PDF)